Marshall Edwards, a specialist oncology company, has appointed Leah Cann to its board of directors. Ms Cann has also been appointed as chairman of the company audit committee.
Subscribe to our email newsletter
The company has also announced that William Rueckert has resigned from its board, and has accepted a position on the board of the company’s 72% shareholder, Novogen.
Ms Cann is an independent research analyst in Newport, Rhode Island. Ms Cann began her career as a research scientist with Memtec and moved to Wall Street in 1992, where she was a research analyst with CIBC Oppenheimer for nearly nine years.
Ms Cann has received a BA in art history and chemistry and an MBA from Stetson University.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.